Pheochromocytoma: state-of-the-art and future prospects.
This review provides current understanding of the pathophysiology of pheochromocytoma and the wide range of associated clinical manifestations that have led to earlier recognition of the disease. In addition, it reviews optimal screening methods and localization techniques that have enhanced the clinician's ability to make the diagnosis with greater certainty. This article will also discuss alternative antihypertensive regimens and innovative anesthetic and surgical procedures that have made successful management more promising than ever before. Areas requiring further development include additional clinical experience with the measurement of plasma metanephrines that have been shown to have high sensitivity and specificity in the diagnosis of sporadic and familial pheochromocytoma, optimizing cost effectiveness of diagnostic imaging, improving the ability to predict and treat malignant pheochromocytoma, and elucidating not only the surgical approach but, perhaps with rapid advances in molecular genetics, ways of preventing familial pheochromocytoma.
Bravo
Emmanuel L
EL
Department of Nephrology and Hypertension, Cleveland Clinic Foundation, Cleveland Ohio 44195, USA. bronofs@ccf.org
Tagle
Rodrigo
R
D000310:Adrenal Gland Neoplasms / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D000368:Aged; D002395:Catecholamines / Q000097:blood / Q000502:physiology; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood / Q000502:physiology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008676:Metanephrine / Q000097:blood / Q000502:physiology; D010673:Pheochromocytoma / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D014057:Tomography, X-Ray Computed
D002395:Catecholamines; D053379:Chromogranin A; D002864:Chromogranins; D008676:Metanephrine